Eukaryotic kinases are known to play an important role in signal transduction pathways by phosphorylating their respective substrates. Abnormal phosphorylations by these kinases have resulted in diseases. Hence inhibitors of kinases are of considerable pharmaceutical interest for a wide variety of disease targets, especially cancers. A number of reports have been published which indicate that eukaryotic-like kinases may complement two-component kinase systems in several bacteria. In Streptomyces sp. such kinases have been found to have a role in formation of aerial hyphae, spores, pigmentation & even in antibiotic production in some strains. Eukaryotic kinase inhibitors are seen to inhibit formation of aerial mycelia in Streptomyces without inhibiting vegetative mycelia. This property has been used to design an assay to screen for eukaryotic kinase inhibitors. The assay involves testing of compounds against Streptomyces 85E ATCC 55824 using agar well diffusion method. Inhibitors of kinases give rise to "bald" colonies where aerial mycelia and sporulation inhibition is seen. The assay has been standardized using known eukaryotic protein kinase inhibiting anticancer agents like AG-490, AG-1295, AG-1478, Flavopiridol and Imatinib as positive controls, at a concentration ranging from 10 µg/well to 100 µg/well. Anti-infective compounds which are not reported to inhibit eukaryotic protein kinases were used as negative controls. A number of microbial cultures have been screened for novel eukaryotic protein kinase inhibitors. Further these microbial extracts were tested in various cancer cell lines like Panc1, HCT116, Calu1, ACHN and H460 at a concentration of 10 µg/mL/ well. The anticancer data was seen correlating well with the Streptomyces kinase assay thus validating the assay.
In eukaryotic cells, protein kinases and phosphatases are involved in multiple signal transduction pathways responsible for proliferation and differentiation of the cells. The protein kinases are primarily of two types, those which phosphorylate tyrosine residues and those which target serine and threonine residues [1, 2] . Abnormal phosphorylation by these kinases can result in irregular cell division causing cancer. Therefore inhibitors of kinases and their cognate phosphatases are of considerable pharmaceutical interest for a wide variety of disease targets especially cancers [3] [4] [5] . Gleevac TM (Imatinib) and Iressa R (Gefitinib) developed for treatment of cancers, are tyrosine kinase inhibitors [6] .
In prokaryotic cells, regulation of cellular activities takes place with the help of two-component regulatory systems involving histidineaspargine kinases. These kinases and their associated response regulators are reported to be involved in adaptive responses such as nitrogen fixation, chemotaxis and the regulation of sporulation in Bacillus species [7, 8] . A number of reports have been published which indicate that eukaryotic-like kinase and phosphatase activities may complement two-component systems in several bacteria, for example flagellar proteins in Pseudomonas aeruginosa [9] and one protein in Mycobacterium tuberculosis [10] . In Myxococcus xanthus protein tyrosine phosphorylation is involved in at least two stages of development, aggregation and sporulation [11] . Furthermore, serine/threonine kinase activity have been demonstrated in other bacteria in which cell-cell interactions take place, including Myxococcus xanthus and cyanobacteria like Synechococcus and Anabaena [12] .
Using phosphotyrosine specific antibodies, it has been shown that several Streptomyces species possess a variety of proteins that are phosphorylated on tyrosine residues [13] . Several serine/threonine protein kinases have been reported in Streptomyces coelicolor [14, 15] . The global inhibitor of eukaryotic protein kinases like staurosporine was seen to inhibit phosphorylation of Streptomyces griseus proteins in in vitro labeling studies. It was found to inhibit the formation of aerial mycelia and spore formation, pigment production and production of the antibiotic streptomycin by S. griseus. Growth of vegetative mycelia was not affected [16] . Observations like these lead to the development of an assay employing Streptomyces to screen for a broad range of inhibitors of eukaryotic protein kinases [17] .
The assay developed by us involved testing of various inhibitors against Streptomyces 85E using agar diffusion method. Three distinct phenotypes were observed in this assay. No zones were observed with inactive samples and negative controls like DMSO and methanol. Clear zones were observed with compounds that inhibited both growth and sporulation, for example antibacterial compounds, indicating that they were cytotoxic to the cells. Finally the desired hazy zone consisting of "bald" colonies where vegetative mycelia of the culture are present but aerial hyphae and sporulation are inhibited, is observed ( Figure 1 ). This morphology was exhibited in the presence of eukaryotic protein kinase inhibitors.
The assay was standardized by testing synthetic anticancer compounds some of which are known to inhibit mammalian protein kinases. The compounds were dissolved in DMSO and tested in the range of 10 µg/ to 100 µg/well. Streptomyces 85E grew very rapidly within 24 hours, the development of aerial hyphae and sporulation taking place between 36 to 48 hours. Compounds known to inhibit wide range of kinases like CDK4, EGFR, PDGFR, Jak2 and bcr-abl gave rise to the hazy zone where aerial hyphae and sporulation of Streptomyces 85E was inhibited ( Table 1 ). The zones appeared as a white haze against the grayish background growth of 85E. The most striking result was seen with the tyrphostin AG-1478, an EGFR inhibitor. It was effective even at a concentration of 10 µg/ well. The inhibitory effect on sporulation was persistent, lasting for 3 to 4 days after entire culture had sporulated. Staurosporine was able to delay the onset of sporulation but only up to 48 hrs, further incubation of the assay plate resulted in sporulation. PI3K inhibitors appeared to respond to the assay by delaying the onset of sporulation only for 24 hours. P276-00, an in-house CDK4 inhibitor developed by Piramal Enterprises Limited, showed a clear zone of 12 mm surrounded by a hazy zone of 21 mm when tested at 90 g/ well indicating that the compound might be a potent kinase inhibitor with slight toxicity at the concentration tested. Akt inhibitor-2, geldanamycin and rapamycin were the exceptions and gave no zone of inhibition indicating they were not active in this assay.
The assay was further validated by testing compounds which are not known to inhibit mammalian protein kinases ( Table 2 ). All the compounds referred in Table 2 were also tested for their Table 3 . However all these samples did not exhibit cytotoxicity. The antibacterials showed a clear zone around the well indicating that the compounds were cidal to 85E strain. Amphotericin B, ISO-1 and metformin were inactive in the assay and gave no zones indicating they were neither Streptomyces kinase inhibitors nor mammalian kinase inhibitors. Rosiglitazone, a PPAR agonist used for the treatment of diabetes mellitus, showed a hazy zone. This may be attributed to the insulin sensitizing activity of rosiglitazone by decreasing the IRS1 (Insulin Receptor Substrate 1) inhibitory serine phosphorylation [18] .
Natural products from microorganisms have shown potential to inhibit kinases in signal transduction pathways [19] . Many known anticancer compounds like staurosporine, mitomycin and doxorubicin have been derived from microbial sources [20] . In this context crude microbial extracts were tested in the assay. Microbial crudes obtained from fermentation and extractions of 50 cultures in four different media (400 samples) were tested in Streptomyces 85E assay in duplicates at a concentration of 200 µg/ well. The same samples were screened against five tumor cell lines and one nontumourigenic cell line. Out of the 400 samples tested, 386 were inactive in kinase assay and only 14 prevented sporulation of Streptomyces 85E and gave rise to hazy zones ( Table 3 ). Eight of them were even slightly cytotoxic at the concentration tested. They displayed clear zone surrounded by hazy zone phenotype. Some cultures like PM0928436 and PM0928568 showed kinase inhibiting activity in multiple media while the rest displayed activity in only one medium. Out of the 400 samples screened in cytotoxicity assay, 384 were inactive. Moreover, all 14 microbial crude extracts inhibiting sporulation of Streptomyces 85E, also exhibited inhibitory activity against cancer cell lines ( Table 3 ). The samples were considered active when they inhibited a minimum of 50% of the cancer cells when tested at a given concentration.
Samples PM0827776 and PM0928590 were exceptions to other 14 samples. PM0827776 was inactive in Streptomyces 85E assay but showed activity when tested against cancer cell lines. This may be due to production of compounds other than protein kinase inhibitors. PM0928590 gave a clear zone against Streptomyces 85 suggesting that it produced an anti-gram positive antibacterial compound, which was also active against cancer cell lines. Eukaryotic protein kinases are potential targets for pharmaceutical intervention as they are the cause of many diseases. Most drug discovery programs involve testing of inhibitors on pure kinase enzymes in vitro [21] . Such conventional assays are subject to a number of limitations and disadvantages. The purified enzymes and their substrates are often expensive and assay protocols involve use of environmentally hazardous radioisotopes. Microbial extracts often contain proteases and phosphatases which interfere in the enzyme assays. Besides, components of culture media also give rise to false positive results. It has also been observed that results seen in in vitro enzymatic assays are not often reproduced in vivo/ex vivo.
In this report we have demonstrated a robust primary screening tool for detecting inhibitors of eukaryotic protein kinases overcoming the limitations mentioned above. This cell based Streptomyces 85E assay is simple and inexpensive alternative to the in vitro enzyme assays for screening large number of crude preparations from microbial extracts. It is visually scorable, less time-consuming and avoids use of expensive instruments which is in compliance with inference reported [22] .
We standardized the assay using synthetic anticancer compounds known to inhibit eukaryotic kinases. Most of the compounds tested gave rise to the "bald" colony morphology thus validating the assay. The assay was very specific for protein kinase inhibitors and is not affected by inhibitors acting on other targets ( Table 2 ). The 85E assay also helps in identifying cytotoxic compounds. The microbial crudes tested also gave the desired results. Extracts which were positive in 85E assay showed activity against cancer cell lines. This proves that data from this assay can be extrapolated for kinase activity in cancer cells. Thus we envisage that the assay can be used as a primary pre-screening tool for short listing potential microbial extracts containing anticancer compounds before carrying out the expensive conventional enzyme based assays. For example the metabolites XR774 and XR336 were detected as potent kinase inhibitors in Streptomyces 85E kinase assay [22] and subsequently shown to inhibit protein tyrosine kinases Fyn, Lck, Abl, EGFR [23] and Src, MAP kinases in vitro [24] . The Streptomyces 85E kinase assay can be used to monitor and purify compounds from microbial extracts using bioassay guided fractionation. Using this technique, six new aminocoumarins, coumabiocins A-F were reported and purified from extracts of Streptomyces sp. L-4-4 [25] .
This assay may not be limited to screening of anticancer compounds only as there are about 500 protein kinases encoded by the human genome [26] and they present a plethora of targets for drug development for the treatment of cancer, immune, cardiovascular, neural and infectious diseases [4, 27] . A further study to pinpoint the exact class of kinases correlating with this assay is warranted.
Experimental
Chemicals: All the chemicals used for standardization of the assay were obtained from Sigma-Aldrich, USA. The media ingredients like beef extract, malt extract, peptone, yeast extract and corn steep liquor used for cultivation and fermentation of microbes were obtained from HiMedia Laboratories Pvt. Ltd, India. Inorganic salts were procured from Merck Specialties Pvt. Ltd, India
Fermentation of microbial cultures: Microbial cultures isolated from various sources were tested for their potential to produce kinase inhibitors. A loopful of the cultures was inoculated into seed medium 274 (1) having the composition (w/v) of glucose (1.5%), corn steep liquor (0.5%), peptone (0.75%), yeast extract (0.75%), calcium carbonate (0.2%) and sodium chloride (0.5%) with a pH value of 7.0. The cultures were allowed to grow on a rotary shaker at 30ºC and 200 rpm for three days. 4% (v/v) solution of the well grown seed were inoculated into four different fermentation media taken in 500 mL Erlenmeyer flasks containing 50 mL of the medium with the following compositions (w/v): SM12 (1) 1290 Natural Product Communications Vol. 10 (7) 2015
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The fermentation was carried on a rotary shaker at 30ºC and 200 rpm for three days.
Extraction and preparation of crude extracts:
The fermentation broth was harvested at three days and extracted with methanol (1:1 v/v) for 1 hour followed by centrifugation at 6000 rpm for 20 minutes. The supernatant was taken and methanol was evaporated under vacuum. The concentrated aqueous extract was divided into two equal parts and processed as follows:
One fraction was passed through 5% (v/v) bed volume of Diaion ® HP20 (SUPELCO) resin and the adsorbed compound eluted using 80% methanol after water wash. The methanolic extract was completely dried using a vacuum concentrator. The second fraction was extracted with ethyl acetate (1:1 v/v) three times. The ethyl acetate extracts were pooled together and dried completely using a vacuum concentrator. The crude microbial extracts obtained were used for the assay. Figure 2 ). The kinase inhibition assay was carried out as described by Waters et al., 2002 [22] with some modifications. ISP4 plates were evenly spread with an overnight culture of Streptomyces 85E ATCC 55824 grown in trypticase soy broth using sterile swabs. Agar plugs were punched out from the plates using a sterile cork borer of 6 mm diameter. Standard compounds and Test samples prepared in dimethyl sulfoxide (DMSO) were added into the wells and the plates were incubated at 30ºC. Flavopiridol, a known CDK4 inhibitor, was used as the positive control and DMSO was used as the negative control. The plates were observed after 24 hours for inhibition of aerial mycelia formation and sporulation and the appearance of "bald" colonies in a hazy zone as positive indication of kinase inhibitors. The zones of total inhibition (clear zones) and partial inhibition (hazy zones) were measured and recorded in millimeter between 36-48 hrs. and 1% Anti-Anti (GIBCO) and grown in T-175 tissue culture flasks (Nunc). MCF-10A (Normal Breast Epithelium Cells), the non-tumourigenic cell line was cultured in Mammary Epithelial Basal Medium (MEBM) with all standard additions (Lonza, Catalog. No CC-3150). All cells were grown at 37ºC with 5% CO 2 . Cells were passaged at 80 -90% confluence. Adherent cells were trypsinised using Trypsin-EDTA (Sigma) and maintained. All cell lines were purchased from ATCC (Rockville, MD, USA).
Kinase inhibition assay (Streptomyces 85E assay): The strain of

Cytotoxicity assay using cancer cells
Sample preparation:
The microbial crude extracts were weighed and dissolved in the required amount of DMSO to give a required stock solution of 20 mg/mL. The extracts were diluted to get a 200fold higher concentration compared to the test concentration. The extracts were tested at a concentration of 10 µg/mL in duplicates.
Experimental Protocol: Cells were plated in a 96-well flat bottom microtiter plates at a cell density of 3000 cells/well. After a 24 hr recovery period to allow the cells to resume exponential growth, 1 µL of the extracts (200X) was added to the wells in duplicates. After 48 hours of incubation, cell toxicity was determined by CCK-8 reagent (Dojindo Molecular Technologies, Inc, Maryland, Japan). 5 µL/well CCK-8 reagent was added and plates were incubated for 2 hours. The extract induced anti-proliferation/toxicity was determined by measuring the absorbance on Tecan Sapphire multifluorescence micro-plate reader (Tecan, Germany, GmbH) at a wavelength of 450 nm and normalized to controls. Flavopiridol (700 nM) was used as positive control and DMSO as the vehicle control. The percent Cytotoxicity was calculated using the following formula, Percent Cytotoxicity = (Reading of vehicle control -Reading of treated cells)/Reading of vehicle control x 100
